Sale of Veriton Pharma to SERB SA

BDO’s M&A Life Sciences team advised the shareholders of Veriton on the sale to SERB, a European specialty pharma business backed by Charterhouse Capital Partners. 

Veriton pioneered the development of unlicensed medicines for neurological and metabolic disorders in areas of high unmet clinical need and has undertaken licensing for several of these medicines in recent years, including Epistatus®.  The business has an attractive portfolio of unlicensed and licensed medicines, and a strong pipeline of products in development. 

BDO led the sale process and provided financial, tax and commercial due diligence services.